Sugi Predict

Sugi Predict / Compounds / SCHEMBL1339079

SCHEMBL1339079

SCHEMBL1339079

CN1C(=O)COc2c(C(=O)O)cccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC6A4 P31645 6/20 0.41
▸ KCNH2 Q12809 6/20 0.41
▸ HTR1A P08908 5/20 0.41
▸ HTR1D P28221 5/20 0.41
▸ HTR1B P28222 5/20 0.41
▸ HTR2A P28223 1/20 0.38
▸ HRH1 P35367 1/20 0.38
▸ HTR3A P46098 1/20 0.38
▸ PDE4D Q08499 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ ALDH1A1 P00352 3/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ MYC P01106 3/20 0.38
▸ NR4A1 P22736 1/20 0.38
▸ PARP1 P09874 1/20 0.38
▸ KDM4E B2RXH2 2/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ CMA1 P23946 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31133320 1.00 SLC6A4 (0.41) SLC6A4KCNH2HTR1AHTR1DHTR1B
Hydrochloric Acid SCHEMBL7288897 0.98 SLC6A4 (0.40) SLC6A4KCNH2HTR1AHTR1DHTR1B
SCHEMBL7288891 0.87 SLC6A4 (0.40) SLC6A4KCNH2HTR1AHTR1DHTR1B
SCHEMBL1339863 0.84 MYC (0.42) SLC6A4KCNH2HTR1AHTR1DHTR1B
SCHEMBL7287945 0.78 PDE3B (0.49) SLC6A4KCNH2HTR2AHRH1HTR3A
SCHEMBL14867323 0.78 HTR1A (0.44) SLC6A4KCNH2HTR1AHTR1DHTR1B
Hydrochloric Acid SCHEMBL7291531 0.77 PDE3B (0.48) SLC6A4KCNH2HTR2AHRH1HTR3A
SCHEMBL7288619 0.77 PDE4D (0.57) SLC6A4KCNH2HTR2AHRH1HTR3A
SCHEMBL474683 0.76 TERT (0.47) SLC6A4KCNH2HTR1AHTR1DHTR1B
SCHEMBL16361881 0.76 HTR1A (0.41) SLC6A4KCNH2HTR1AHTR1DHTR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110105491-A1 THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-05-05 — — US claimed
EP-2185512-B1 TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2010-12-29 — — EP claimed
US-20100222600-A1 AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2010-09-02 — — US claimed
EP-2185512-A2 TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-05-19 — — EP claimed
WO-2010004507-A1 THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2010-01-14 — — WO claimed
EP-2069332-A2 AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS Actelion Pharmaceuticals Ltd. (CH) 2009-06-17 — — EP claimed
WO-2009016560-A2 TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-02-05 — — WO claimed
WO-2008020405-A2 AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2008-02-21 — — WO claimed
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 — — US disclosed
EP-3856178-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-03-11 — — EP disclosed
EP-3966226-B1 MASP INHIBITORY COMPOUNDS AND USES THEREOF BAYER AG (DE) 2025-12-24 — — EP disclosed
US-12503491-B2 MASP inhibitory compounds and uses thereof BAYER AKTIENGESELLSCHAFT (DE) 2025-12-23 — — US disclosed
US-20240124522-A1 MASP INHIBITORY COMPOUNDS AND USES THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2024-04-18 — — US disclosed
US-11820766-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-11-21 — — US disclosed
WO-2009016560-A2 TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-02-05 — — WO disclosed
WO-2008038251-A2 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2008-04-03 — — WO disclosed
WO-2008020405-A2 AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2008-02-21 — — WO disclosed
EP-0313393-B1 Benzoxazine compounds and pharmaceutical use thereof YOSHITOMI PHARMACEUTICAL (JP) 1994-03-16 — — EP disclosed
US-4892872-A ANTIEMETICS, ANTINAUSEA YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1990-01-09 — — US disclosed
EP-0313393-A2 Benzoxazine compounds and pharmaceutical use thereof Yoshitomi Pharmaceutical Industries, Ltd. (JP) 1989-04-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105491-A1 THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, OXTR SLC6A4 440/4885KCNH2 2077/4885HTR1A 109/4885
US-12503491-B2 MASP inhibitory compounds and uses thereof MASP2, SERPINB1, SPINT2 SLC6A4 3983/4885KCNH2 4324/4885HTR1A 4122/4885
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH SLC6A4 583/4885KCNH2 668/4885HTR1A 113/4885
US-20100222600-A1 AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPY1R SLC6A4 537/4885KCNH2 753/4885HTR1A 58/4885
US-20240124522-A1 MASP INHIBITORY COMPOUNDS AND USES THEREOF MASP2, SERPINB1, SPINT2 SLC6A4 3983/4885KCNH2 4324/4885HTR1A 4122/4885
US-11820766-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP SLC6A4 1888/4885KCNH2 2603/4885HTR1A 192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.